Cancer Investigation最新文献

{"title":"Global, Regional, and National Burden of Ovarian Cancer Attributable to High Body-Mass Index Among Women Aged 55 Years and Older: A GBD 2021 Analysis.","authors":"Jingfei Zheng, Hongfeng Li, Xuehe Li, Jia Bian, Fang Zhang","doi":"10.1080/07357907.2026.2681848","DOIUrl":"10.1080/07357907.2026.2681848","url":null,"abstract":"<p><strong>Background: </strong>High body-mass index (BMI) defined in the Global Burden of Disease Study as BMI above the theoretical minimum risk exposure level, is an established modifiable risk factor for ovarian cancer, particularly among older women. However, a comprehensive assessment of the global disease burden attributable to high BMI, including its spatiotemporal evolution and underlying drivers, remains lacking, particularly for older women.</p><p><strong>Methods: </strong>Using data from the Global Burden of Disease Study 2021, we analyzed disability-adjusted life years (DALYs) and deaths from ovarian cancer attributable to high BMI among women aged ≥55 years from 1990 to 2021. We examined temporal trends, geographic disparities by Socio-Demographic Index (SDI), region, and nation, and performed decomposition analyses to identify contributions from population growth, aging, and epidemiological changes.</p><p><strong>Results: </strong>Globally, the attributable burden increased from 1990 to 2021, with population growth as the main driver. of rising absolute DALYs (86.72) and deaths (85.17). Marked socioeconomic disparities were observed. While high-SDI regions had the highest age-standardized rates in 2021, they showed declining trends., whereas low-middle and low-SDI regions experienced the most rapid increases. Regionally, the fastest increases occurred in South Asia, Southeast Asia, and East Asia, while nationally the largest rises were observed in Timor-Leste, Viet Nam, and Bangladesh. In these settings, epidemiological changes were the dominant contributor to increasing burden.</p><p><strong>Conclusions: </strong>The global burden of ovarian cancer due to high BMI is rising and unequally distributed across SDI regions. While population growth drives the overall increase, escalating obesity prevalence is the key driver in rapidly developing regions. Targeted obesity prevention, improved early detection, and strengthened health-care systems should be prioritized, particularly in high-growth regions. Future studies should improve data quality in low-resource settings and explore cost-effective interventions.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"1067-1078"},"PeriodicalIF":2.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148238791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Cancer Drug Treatments Using Big Data Integration of Genomic and Clinical Data for Personalized Medicine.","authors":"Amruta Mohan Chimanna, Harshala Shingne, Shabana Pathan, Diptee Chikmurge, Leena Vinod Patil","doi":"10.1080/07357907.2026.2703811","DOIUrl":"10.1080/07357907.2026.2703811","url":null,"abstract":"<p><p>Personalized cancer care depends on the seamless integration of genetic profiles, medical histories, and continuous patient monitoring to optimize therapeutic outcomes. Current clinical strategies struggle to combine these disparate, highly heterogeneous data streams, frequently resulting in incomplete diagnostic evaluations and suboptimal treatment selections. Factors such as poor cross-platform compatibility, low prediction precision, and the omission of real-time clinical parameters limit the practical deployment of precision medicine. To address these limitations, this study introduces BigCancerNet (BCN), a robust big data framework that merges multi-source information and uses a Graph Neural Network for Cancer Treatment Optimization (GNN-CTO) to accurately forecast individual drug responses and patient survival trajectories. This initiative is driven by the aspiration to boost treatment success, reduce toxic side effects, and permit flexible, patient-centric therapeutic adaptations. The processing pipeline comprises collecting genomic, clinical, and real-time biometric data from numerous repositories, including The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), Cancer Dependency Map (DepMap), and hospital Electronic Health Records (EHRs). Data preprocessing applies Deep Embedding Networks (D2EN) to regularize genomic sequences, handle missing values, and standardize clinical features. The Hybrid Multi-Omics Fusion Algorithm (HMOFA) integrates these diverse datasets, harmonizing genomic, clinical, and wearable information while minimizing batch effects. The GNN-CTO model captures complex, nonlinear relationships among mutations, clinical factors, and drug responses, while Real-Time Model Adaptation with Dynamic Feedback Loop (RT-MADFL) continuously updates predictions. Results demonstrate reduced RMSE (0.160-0.245) and MAE (0.110-0.180), high stability with fold accuracy variance below 0.3%, fast training (12-15s per epoch), and prediction metrics exceeding 91%. Future work includes expanding to multi-cancer cohorts and integrating explainable AI to support transparent clinical decision-making.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"1123-1141"},"PeriodicalIF":2.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redefining Oligometastatic Pancreatic Ductal Adenocarcinoma: Biology, Diagnosis, and Precision Multimodal Therapy.","authors":"Takehiro Okabayashi, Motoyasu Tabuchi, Teppei Tokumaru, Sunao Uemura, Shuta Tamura","doi":"10.1080/07357907.2026.2703787","DOIUrl":"10.1080/07357907.2026.2703787","url":null,"abstract":"<p><strong>Background: </strong>Given the dismal prognosis of metastatic pancreatic ductal adenocarcinoma, oligometastatic disease (OM-PDAC) has emerged as a distinct clinical entity, challenging systemic-only paradigms via advanced multimodal therapies.</p><p><strong>Recent findings: </strong>Retrospective data indicate that anatomical burden alone inadequately guides patient selection. Optimal management requires integrating high-quality imaging, liquid biopsies, and molecular profiling to identify biologically favorable disease. Patients achieving durable responses to induction chemotherapy show improved survival following local interventions like conversion surgery, stereotactic radiotherapy, or ablation.</p><p><strong>Conclusion: </strong>OM-PDAC management must transition from anatomy-based criteria toward biologically driven, precision multidisciplinary therapy validated by prospective trials.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"1052-1066"},"PeriodicalIF":2.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Evolving Role of Surgery in Hepatocellular Carcinoma Management: From Resection to Multidisciplinary Strategy.","authors":"Takehiro Okabayashi, Motoyasu Tabuchi, Teppei Tokumaru, Sunao Uemura, Shuta Tamura","doi":"10.1080/07357907.2026.2681850","DOIUrl":"10.1080/07357907.2026.2681850","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) frequently develops in the setting of chronic liver disease, making its management uniquely complex and historically centered on surgery.</p><p><strong>Recent findings: </strong>Advances in locoregional therapies, molecular targeted agents, and immune checkpoint inhibitors have profoundly transformed treatment algorithms. Immunotherapy-based combinations achieve deep and durable responses, enabling downstaging, conversion surgery, and perioperative strategies previously considered unfeasible.</p><p><strong>Conclusion: </strong>In the contemporary era, surgeons serve not only as technical operators but as strategic leaders within multidisciplinary teams, integrating evolving systemic and local therapies to achieve durable oncologic outcomes.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"1039-1051"},"PeriodicalIF":2.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sub-National Disparities in the Incidence of Cancers Associated with Modifiable Risk Factors: An Analysis of Canadian CiNA Data (2010-2022).","authors":"Omar Abdel-Rahman","doi":"10.1080/07357907.2026.2699223","DOIUrl":"10.1080/07357907.2026.2699223","url":null,"abstract":"<p><strong>Objective: </strong>To examine subnational disparities between Canadian territories and provinces [covered in the Cancer in North America (CiNA) dataset] in the incidence of cancers grouped by association with modifiable risk factors (2010-2022).</p><p><strong>Methods: </strong>CiNA public dataset was accessed, and information from nine Canadian jurisdictions about the following categories of cancers was included (cancers associated with physical inactivity; obesity; alcohol consumption; tobacco use; and Human Papillomavirus [HPV]-associated cancers). Age-standardized incidence rates (ASIRs) were initially calculated for all years of the study (2010-2022) for each of the five categories, comparing ASIRs of territories vs ASIRs of provinces.</p><p><strong>Results: </strong>Among the five categories analyzed here, ASIRs were higher in the territories compared to provinces for cancers associated with physical inactivity (relative disparity= 1.05), cancers associated with obesity (relative disparity= 1.16), cancers associated with alcohol consumption (relative disparity = 1.21), cancers associated with tobacco use (relative disparity = 1.39), but not for HPV-associated cancers, where ASIR was numerically lower in the territories (relative disparity = 0.81).</p><p><strong>Conclusion: </strong>Within the Canadian jurisdictions covered in the CiNA public dataset, pooled territorial jurisdictions have a higher incidence of cancers associated with physical inactivity, obesity, alcohol consumption, and tobacco use, but not a higher incidence of HPV-associated cancers, compared with pooled provincial jurisdictions.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"1107-1115"},"PeriodicalIF":2.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148429891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial Differences in Outcomes Among Patients with Multiple Myeloma Treated at a Myeloma Center of Excellence: A Retrospective Cohort Study.","authors":"Jordan Lee Cottrell, Anton Casillas, Kingsley C Nnawuba, Savannah J Tidd, Samantha Elizabeth Robinson, Mohammod Mahmudur Rahman, Chinemerem M Emeasoba, Anup Kumar Trikannad, Hanna Jensen","doi":"10.1080/07357907.2026.2703020","DOIUrl":"10.1080/07357907.2026.2703020","url":null,"abstract":"<p><p>Multiple myeloma (MM) is a hematologic malignancy of monoclonal plasma cells. Black individuals have a higher incidence of MM than other races, and numerous studies have described potential disparities in myeloma care. In this retrospective study, we investigated outcomes of MM within a single academic institution with a dedicated myeloma Center of Excellence in a rural state. Data from a single academic institution's cancer registry was analyzed for patients diagnosed with MM between 2015 and 2024. Demographic, treatment, and outcome data were collected. The association between survival and race was examined using bivariate analyses, a log-rank test, and both univariable and multivariable Cox proportional hazards modeling. No statistically significant differences in 1-, 3-, and 5-year survival rates between the racial groups were observed. Medicaid insurance, higher age at diagnosis, active cancer status, negative family history of cancer, decreased alcohol use, and higher comorbidity burden were found to be significantly associated with increased mortality, independent of race. Our study found that Black patients with MM treated at this single academic institution with a dedicated myeloma center had similar survival rates when compared to White patients. Centralized care and dedicated Centers of Excellence may help mitigate racial disparities in myeloma care.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"1116-1122"},"PeriodicalIF":2.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148520000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarker-Guided Adjuvant Therapy in Stage II/III Colon Cancer: A Systematic Review of Current Evidence and Clinical Implications.","authors":"Nabil Ismaili","doi":"10.1080/07357907.2026.2696794","DOIUrl":"10.1080/07357907.2026.2696794","url":null,"abstract":"<p><strong>Background: </strong>The management of resectable stage II/III colon cancer (CC) has long relied on clinicopathological features and fluoropyrimidine-based adjuvant chemotherapy. However, this approach fails to capture the profound biological heterogeneity of the disease, often leading to overtreatment or undertreatment. A new generation of biomarkers now allows a shift toward precision oncology, refining prognosis and predicting therapeutic response. This systematic review critically appraises the evidence for biomarker-guided adjuvant therapy.</p><p><strong>Methods: </strong>A systematic literature search of PubMed/MEDLINE and Cochrane Library was conducted up to December 2025. Eligible studies included phase II/III randomized controlled trials, prospective cohorts, and large retrospective analyses with independent validation. Due to significant heterogeneity in interventions, settings, and biomarker assays, a narrative synthesis was performed following PRISMA guidelines.</p><p><strong>Results: </strong>Of 1,245 screened records, 52 studies were included. Universal MMR testing is mandatory: deficient MMR (dMMR)/microsatellite instability-high (MSI-H) tumors represent approximately 15% of stage II/III cases. For stage III CC, the phase III ATOMIC trial demonstrated that adding atezolizumab to mFOLFOX significantly improved 3-year disease-free survival (DFS) versus chemotherapy alone (86.4% vs. 76.6%; HR 0.50; 95% CI 0.34-0.72). Additionally, neoadjuvant immunotherapy (NICHE-2) achieved pathological complete response rates of 68% and 3-year DFS of 100%. In microsatellite-stable (MSS) tumors, integrated analysis of KRAS/BRAF mutations and tumor laterality refines prognosis. Pooled analyses of stage III patients showed that KRAS codon 12 mutations are independently associated with shorter time to recurrence and overall survival, specifically in left-sided tumors. Perioperative CEA retains prognostic value, and its incorporation into risk stratification models improves performance. ctDNA enables dynamic minimal residual disease detection; the DYNAMIC-III trial reduced oxaliplatin use by approximately 60% with comparable 3-year recurrence-free survival (85.3% vs. 88.1%). Large observational studies have confirmed the strong prognostic value of postoperative ctDNA, with hazard ratios for recurrence >5. Toxicity biomarkers (DPYD, UGT1A1) should be assessed before treatment.</p><p><strong>Conclusions: </strong>The adjuvant treatment of stage II/III colon cancer is evolving from a one-size-fits-all approach to biomarker-driven precision oncology. A stepwise, resource-aware framework is proposed: universal MMR testing as the gateway, then CEA, mutational profiling, and selective ctDNA. Prospective validation of integrated models is urgently needed, especially in under-represented populations (elderly, organ impairment, ethnic minorities).</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"1142-1159"},"PeriodicalIF":2.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148389933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Profiling Immune-Related Adverse Events Associated with Imatinib: A Two-Decade Real-World Safety Study Based on FDA Adverse Event Reporting System.","authors":"Yongfeng Zhu, Yanbin Zeng, Wanlong Lin, Wei Zhuang, Haibo Qiu","doi":"10.1080/07357907.2026.2696796","DOIUrl":"10.1080/07357907.2026.2696796","url":null,"abstract":"<p><strong>Background: </strong>Emerging evidence suggests that imatinib may influence immune pathways and be associated with adverse events (AE) with potential immune involvement, some leading to treatment interruption or irreversible damage. However, systematic characterization remains limited.</p><p><strong>Methods: </strong>We analyzed FDA Adverse Event Reporting System data (2004-2024), extracting reports with imatinib as the primary suspect. Immune-related AEs were identified using standardized MedDRA queries. Disproportionality analyses were performed using reporting odds ratio (ROR), proportional reporting ratio, multi-item gamma Poisson shrinker, and Bayesian confidence propagation neural network. Signals meeting all thresholds were considered positive. ROR was the primary reference for signal strength.</p><p><strong>Results: </strong>A total of 15,748 patients experienced 31,400 target events, yielding 74 safety signals. Signals of organ dysfunction-particularly in the liver, kidney, and lung-were identified. High-signal with notable immune or inflammatory features included necrotizing panniculitis (ROR 164.69, 95% CI 90.65-299.22), inclusion body myositis, polyserositis, and chronic cutaneous lupus erythematosus. Frequent events like fluid retention and cytopenia were relatively nonspecific. Signals showed heterogeneity across sex and age subgroups and tended to occur in the mid-to-late treatment period.</p><p><strong>Conclusions: </strong>Imatinib is associated with diverse signals with potential immune involvement, exhibiting age- and sex-related heterogeneity. Further prospective and mechanistic studies are warranted.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"1079-1092"},"PeriodicalIF":2.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148390012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic Investigation of Key Drivers of Lung Adenocarcinoma: A Focus on Genes, Pathways, and miRNAs.","authors":"Maryam Navaei, Fatemeh Karami, Aria Jahanimoghadam, Sara Zareei, Babak Khorsand","doi":"10.1080/07357907.2026.2696797","DOIUrl":"10.1080/07357907.2026.2696797","url":null,"abstract":"<p><p>Lung cancer remains a leading cause of cancer-related mortality worldwide, largely due to its asymptomatic progression in early stages and the development of drug resistance. Non-small cell lung cancer (NSCLC) accounts for 80% of all lung cancer cases, and lung adenocarcinoma (LUAD) is the most prevalent subtype. Despite advancements in treatment, the 5-year survival rate for LUAD remains low. A comprehensive literature review across various databases was conducted to curate a robust set of LUAD-associated genes. These genes were used to construct a weighted network based on KEGG pathway similarity, followed by clustering, hub gene detection, and gene ontology analysis. In parallel, a protein-protein interaction (PPI) network and a gene-miRNA regulatory network were established to provide additional layers of molecular insight. Our analysis identified 48 genes as central to LUAD pathogenesis. Several of these genes, along with their corresponding miRNAs, exhibited significant dysregulation in LUAD tissues. The hub genes PIK3CA, BRAF, EGFR, ERBB2, FGFR3, MTOR, and TP53, along with KRAS, MET, and FGFR2, emerged as potential biomarkers. Additionally, miR-17-5p and miR-27a-3p were highlighted as novel biomarker candidates with strong implications in LUAD biology. In conclusion, this study provides a refined list of genes and miRNAs with high relevance for LUAD, alongside key signaling pathways central to disease progression. These findings establish a foundation for future studies and support the development of targeted therapeutic strategies aimed at improving clinical outcomes in LUAD.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"1093-1106"},"PeriodicalIF":2.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148410466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory Single-Cell Analysis of NK-Annotated Cells Across Marrow Compartments in Prostate Cancer Bone Metastasis.","authors":"Kehao Pan, Nianzeng Xing","doi":"10.1080/07357907.2026.2744214","DOIUrl":"https://doi.org/10.1080/07357907.2026.2744214","url":null,"abstract":"<p><p>Prostate cancer preferentially colonizes bone, where marrow compartments differ in tissue structure and immune composition. We reanalyzed a 920,521-cell integrated prostate cancer atlas containing 38,842 NK-annotated cells from 126 sample identifiers, focusing on one bone-marrow cohort of 16 subjects and 32 samples. Distal marrow from patients with bone metastasis was compared with nonmalignant marrow from unrelated hip-replacement controls, while complete within-patient pairs were used for local comparisons. Sample- or subject-level composition, pseudobulk expression, pathway, and microenvironment analyses treated biological units, not cells, as replicates. The inherited CytokNKs_GZMH label was more frequent in distal marrow than in controls (25.4% versus 2.0%; centered log-ratio effect 2.82; false-discovery rate 0.0367). Paired tumor-versus-distal comparisons showed higher relative abundance of ImmSuppNKs_CREM and lower proportions of several other inherited labels at the 10% false-discovery threshold. A pooled comparison identified 62 differential genes within RegNKs_IL7R and generated a 24-gene exploratory program; distal-only models had no genes meeting the joint cutoff. Frequent T-cell- and myeloid-marker detection precluded assignment of this population as a validated NK subset. Program separation within the discovery cohort was subject to gene-selection bias and did not establish predictive performance. Full-atlas analyses described compartment-associated composition differences and candidate ligand-receptor expression pairs. Donor characteristics, treatment, sampling site, specimen processing, and annotation uncertainty remain unresolved sources of confounding. These findings are hypothesis-generating associations in recovered NK-annotated cells, not evidence of a metastasis-specific field effect, a regulatory NK population, or clinical utility.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"1-21"},"PeriodicalIF":2.2,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}